{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:59:46Z","timestamp":1786993186312,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":1095,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Helsinn Healthcare SA"},{"name":"Helsinn Healthcare SA"},{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jpainsymman.2020.03.034","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T23:58:20Z","timestamp":1586303900000},"page":"568-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase 3 Study of Palonosetron IV Infusion Vs. IV Bolus for\u00a0Chemotherapy-Induced Nausea and Vomiting Prophylaxis After Highly Emetogenic Chemotherapy"],"prefix":"10.1016","volume":"60","author":[{"given":"Meinolf","family":"Karthaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Voisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2020.03.034_bib1","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib2","first-page":"497","article-title":"Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib3","first-page":"708","article-title":"Chemotherapy-induced nausea and vomiting in routine practice: a European perspective","volume":"12","author":"Glaus","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib4","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0959-8049(02)00674-3","article-title":"Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists","volume":"39","author":"Hesketh","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","article-title":"Proposal for classifying the acute emetogenicity of cancer chemotherapy","volume":"15","author":"Hesketh","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib7","first-page":"S43","article-title":"Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2014state of the art","volume":"19","author":"Grunberg","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib10","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib11","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2012.01.046","article-title":"Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting","volume":"684","author":"Rojas","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdq600","article-title":"Update and new trends in antiemetic therapy: the continuing need for novel therapies","volume":"22","author":"Feyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib15","series-title":"Aloxi\u00ae (palonosetron HCl) injection for intravenous use [prescribing information]","year":"2018"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib16","series-title":"Aloxi (palonosetron HCl) injection for intravenous use; Aloxi\u00ae (palonosetron) capsules [summary of product characteristics]","year":"2018"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib17","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1517\/14656566.2014.972366","article-title":"Palonosetron for the treatment of chemotherapy-induced nausea and vomiting","volume":"15","author":"Navari","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib18","series-title":"Akynzeo\u00ae (netupitant and palonosetron) capsules; Akynzeo\u00ae (fosnetupitant and palonosetron) for injection [prescribing information]","year":"2018"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib19","series-title":"Akynzeo\u00ae [summary of product characteristics]","year":"2015"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1177\/0091270006291625","article-title":"Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects","volume":"46","author":"Shah","year":"2006","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib22","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","article-title":"A\u00a0phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy","volume":"25","author":"Gralla","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib24","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A\u00a0randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib25","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","article-title":"Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","article-title":"A\u00a0phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy","volume":"17","author":"Aapro","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib27","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib29","first-page":"1507","article-title":"A\u00a0phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy","volume":"20","author":"Aogi","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib30","first-page":"615","article-title":"Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy","volume":"20","author":"Feinberg","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1742-1241.2012.02969.x","article-title":"Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy","volume":"66","author":"Longo","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.suponc.2011.06.007","article-title":"Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial","volume":"10","author":"Celio","year":"2012","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib33","first-page":"653","article-title":"Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin\/cyclophosphamide-induced nausea and vomiting","volume":"20","author":"Hesketh","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib34","first-page":"2583","article-title":"Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy","volume":"20","author":"Noor","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3109\/10428194.2013.813498","article-title":"Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy","volume":"55","author":"Choi","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib36","first-page":"2343","article-title":"Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study","volume":"20","author":"Yavas","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib37","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1517\/14740338.2014.954546","article-title":"5-Hydroxytryptamine3 receptor antagonists and cardiac side effects","volume":"13","author":"Brygger","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib38","first-page":"621","article-title":"Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers","volume":"24","author":"Morganroth","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib39","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","article-title":"One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis","volume":"24","author":"Okada","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib40","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","article-title":"Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives","volume":"10","author":"Salsman","year":"2012","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib43","first-page":"e1127","article-title":"Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey","volume":"1","author":"Aapro","year":"2018","journal-title":"Cancer Rep"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib44","first-page":"557","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib45","first-page":"4099","article-title":"Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey","volume":"27","author":"Dielenseger","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib46","first-page":"3297","article-title":"Impact and management of chemotherapy\/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists\/oncology nurses and patients: a cross-sectional multinational survey","volume":"23","author":"Vidall","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/651879","article-title":"A\u00a0review of NEPA, a novel fixed antiemetic combination with the potential for enhancing guideline adherence and improving control of chemotherapy-induced nausea and vomiting","volume":"2015","author":"Hesketh","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib49","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/cam4.2091","article-title":"Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: efficacy data from 2 randomized, double-blind phase III studies","volume":"8","author":"Schwartzberg","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib51","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/fon-2020-0187","article-title":"Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life","volume":"16","author":"Karthaus","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib52","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdy169","article-title":"Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy","volume":"29","author":"Schwartzberg","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2020.03.034_bib53","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0527","article-title":"Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy","volume":"25","author":"Schwartzberg","year":"2020","journal-title":"Oncologist"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392420301871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392420301871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:29:58Z","timestamp":1760131798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392420301871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0885392420301871"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.03.034","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 3 Study of Palonosetron IV Infusion Vs. IV Bolus for\u00a0Chemotherapy-Induced Nausea and Vomiting Prophylaxis After Highly Emetogenic Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}